Adults 18 to 60, any sex, with Hypertension. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Forearm Blood FlowPrimary· After four-week treatment with each crossover drug
Forearm blood flow measured by strain gauge plethysmography before and after intra-arterial peptide infusion
Group
Value
95% CI
LCZ696
2.46
2.46 – 2.46
Valsartan
2.99
2.99 – 2.99
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data were collected over the full duration of the study - approximately 12 weeks..
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to test the hypothesis that combined angiotensin receptor blockade (ARB)/neprilysin (NEP) inhibition potentiates the effects of exogenous bradykinin, substance P, and brain natriuretic peptide (BNP) on forearm blood flow or endothelial tissue-type plasminogen activator (t-PA) release compared to ARB alone. A secondary goal is to determine if there is an interactive effect of ARB/NEP inhibition and dipeptidyl peptidase 4 (DPP4) inhibition on responses to these peptides.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
NCT07331389 — A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin
· Phase 1
· recruiting
NCT07491718 — Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy
· NA
· recruiting
NCT06771245 — A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensi
· Phase 3
· not yet recruiting
NCT06643819 — Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-202A
· Phase 3
· recruiting
NCT06501651 — Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
· Phase 4
· not yet recruiting
Other recruiting trials for Hypertension
Currently open trials in the same condition.
NCT07413159 — The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans A
· NA
· recruiting
NCT07361276 — Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in the Public Primary Care S
· recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
· NA
· recruiting
NCT07238400 — Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia
· Phase 2
· recruiting
NCT07135505 — Early Time-Restricted Eating in Older Adults With Hypertension
· NA
· recruiting
Other Vanderbilt University Medical Center trials
Trials by the same sponsor.
NCT07005037 — Swallowing Impairments in ICU Survivors and Community-Dwelling Adults
· not yet recruiting
NCT07527273 — Cognitive Enhancement in Recurrent Depression (The COG-D-R Study)
· NA
· not yet recruiting
NCT07295288 — Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis
· Phase 4
· not yet recruiting
NCT07431541 — Topical Carboxytherapy Paste Following Microneedling
· Phase 1, PHASE2
· not yet recruiting
NCT07224711 — The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery
· Phase 4
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University Medical Center
Last refreshed: 3 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03738878.